6-K - NeuroSense Therapeutics Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

NeuroSense Therapeutics Ltd. announced additional long-term survival data from its completed PARADIGM Phase 2b trial of PrimeC in ALS patients, showing a statistically significant 65% reduction in risk of death (HR 0.35, p=0.0037) and greater than 14-month median survival benefit (36.3 months vs. 21.4 months, p=0.0218). These findings strengthen the clinical data package as the company engages regulators for late-stage development.

Key Takeaways

1PrimeC achieved median survival of 36.3 months vs. 21.4 months for placebo crossover (over 14-month improvement, p=0.0218)

265% reduction in risk of death (HR 0.35, 95% CI 0.17–0.71, p=0.0037)

3Data from PARADIGM Phase 2b trial (68 ALS patients, 2:1 randomization, 6-month double-blind)

4Survival benefit sustained over time with consistent separation between arms

5NeuroSense engaging regulatory authorities for PrimeC late-stage development

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Exhibits (2)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

PRESS RELEASE DATED FEBRUARY 18, 2026